Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$237.83 USD
+1.13 (0.48%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $237.97 +0.14 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Income Statements
Fiscal Year end for Alnylam Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1,828 | 1,037 | 844 | 493 | 220 |
Cost Of Goods | 310 | 169 | 140 | 78 | 25 |
Gross Profit | 1,518 | 869 | 704 | 415 | 195 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,800 | 1,654 | 1,413 | 1,243 | 1,134 |
Income After Depreciation & Amortization | -282 | -785 | -709 | -828 | -939 |
Non-Operating Income | -30 | -186 | 0 | 57 | 54 |
Interest Expense | 121 | 156 | 143 | 85 | 0 |
Pretax Income | -434 | -1,127 | -852 | -856 | -885 |
Income Taxes | 7 | 4 | 1 | 3 | 1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -440 | -1,131 | -853 | -858 | -886 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -440 | -1,131 | -853 | -858 | -886 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -185 | -700 | -619 | -754 | -885 |
Depreciation & Amortization (Cash Flow) | 97 | 86 | 90 | 74 | 54 |
Income After Depreciation & Amortization | -282 | -785 | -709 | -828 | -939 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 124.91 | 121.69 | 118.45 | 114.99 | 109.26 |
Diluted EPS Before Non-Recurring Items | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 |
Diluted Net EPS (GAAP) | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 |
Fiscal Year end for Alnylam Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 494.33 | 439.72 | 750.53 | 318.75 |
Cost Of Goods | NA | 65.98 | 85.86 | 84.31 | 85.37 |
Gross Profit | NA | 428.36 | 353.86 | 666.22 | 233.38 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 471.80 | 470.26 | 452.36 | 463.22 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -43.44 | -116.40 | 213.86 | -229.84 |
Non-Operating Income | NA | 15.10 | 10.06 | -32.23 | -14.34 |
Interest Expense | NA | 35.25 | 31.34 | 30.89 | 30.04 |
Pretax Income | NA | -63.59 | -137.69 | 150.74 | -274.21 |
Income Taxes | NA | 2.35 | 0.18 | 2.99 | 1.82 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -65.94 | -137.87 | 147.75 | -276.02 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -65.94 | -137.87 | 147.75 | -276.02 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 126.14 | 125.61 | 131.34 | 124.66 |
Diluted EPS Before Non-Recurring Items | NA | -0.52 | -1.10 | 1.15 | -2.21 |
Diluted Net EPS (GAAP) | NA | -0.52 | -1.06 | 1.15 | -2.21 |